scispace - formally typeset
W

William Likosky

Researcher at Kaiser Permanente

Publications -  34
Citations -  3377

William Likosky is an academic researcher from Kaiser Permanente. The author has contributed to research in topics: Multiple sclerosis & Interferon beta-1a. The author has an hindex of 24, co-authored 34 publications receiving 3247 citations. Previous affiliations of William Likosky include American Academy of Neurology & Centers for Disease Control and Prevention.

Papers
More filters
Journal ArticleDOI

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.

TL;DR: Clinical trials study patients for only short periods of time (2 or 3 years) and, therefore, use only short-term outcome measures to assess efficacy, and evaluation of the relative effectiveness of different therapies requires consideration of which outcome measure or measures are relevant to the goals of therapy.
Journal ArticleDOI

Treatment of Depression Improves Adherence to Interferon Beta-1b Therapy for Multiple Sclerosis

TL;DR: Findings support previous findings that patients report increased depression after initiating therapy with IFN beta-1b and suggest that treating patient-reported depression increases adherence to treatment.
Journal ArticleDOI

Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis

TL;DR: Depressive symptomatology decreased significantly in the CMS condition compared with the UCC condition, and adherence to interferon beta-1a, a disease-modifying medication for the treatment of MS, was significantly better at the 4-month follow-up among patients who received CMS as compared with those in theUCC condition.
Journal ArticleDOI

The psychosocial impact of multiple sclerosis: exploring the patient's perspective.

TL;DR: The authors examined subjective patient experiences of the psychosocial consequences of multiple sclerosis (MS) and found that benefit-finding is a substantial and poorly understood part of the illness experience for MS patients.